

## Special Issue

# Intratumoral Heterogeneity in Brain Cancers

### Message from the Guest Editor

Brain tumors are complex ecosystems containing a significant number of malignant and nonmalignant cells. Clarifying the extent of intratumoral heterogeneity (ITH) in brain tumors is an important goal as ITH provides fuel for acquired resistance to targeted therapies. To achieve this, new strategies are needed to precisely identify distinct populations of malignant and nonmalignant cells in brain tumors, along with their defining molecular features. We are pleased to invite submissions to this Special Issue on the topic of intratumoral heterogeneity in brain cancers. This Special Issue aims to collect a representative sample of cutting-edge experimental and computational strategies for analyzing ITH in different types of brain cancer. Review articles on the topic of ITH in brain cancers are also welcome. Themes of particular interest include clonal evolution, the tumor microenvironment, and multiomics/multiscale integration.

---

### Guest Editor

Dr. Michael Oldham

Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA

---

### Deadline for manuscript submissions

31 March 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/205271](https://mdpi.com/si/205271)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)